文献类型：期刊文献

英文题名：New small-molecule drug design strategies for fighting resistant influenza A

作者：Shen, Zuyuan[1,2];Lou, Kaiyan[1,2];Wang, Wei[1,2,3]

机构：[1]E China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab Chem Biol, Shanghai 200237, Peoples R China;[2]E China Univ Sci & Technol, State Key Lab Bioengn, Shanghai 200237, Peoples R China;[3]Univ New Mexico, Dept Chem & Chem Biol, Albuquerque, NM 87131 USA

年份：2015

卷号：5

期号：5

起止页码：419

外文期刊名：ACTA PHARMACEUTICA SINICA B

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000361896000005)】；

基金：The work was supported by the Fundamental Research Funds for the Central Universities (Kaiyan Lou) and East China University of Science and Technology (start-up funds to Wei Wang). We also would like to thank William Hanafin at the Univeristy of Illinois for his editing suggestions.

语种：英文

外文关键词：Influenza A virus; Drug discovery; Resistance; M2 ion channel; Neuramindase

摘要：Influenza A virus is the major cause of seasonal or pandemic flu worldwide. Two main treatment strategies vaccination and small molecule anti-influenza drugs are currently available. As an effective vaccine usually takes at least 6 months to develop, anti-influenza small molecule drugs are more effective for the first line of protection against the virus during an epidemic outbreak, especially in the early stage. Two major classes of anti-influenza drugs currently available are admantane-based M2 protein Mockers (amantadine and rimantadine) and neuraminidase (NA) inhibitors (oseltamivir, zanamivir, and peramivir). However, the continuous evolvement of influenza A virus and the rapid emergence of resistance to current drugs, particularly to amantadine, rimantadine, and oseltamivir, have raised an urgent need for developing new anti -influenza drugs against resistant forms of influenza A virus. In this review, we first give a brief introduction of the molecular mechanisms behind resistance, and then discuss new strategies in small-molecule drug development to overcome influenza A virus resistance targeting mutant M2 proteins and neuraminidases, and other viral proteins not associated with current drugs. (c) 2015 Chinese Pharmaceutical Association and Institute of Materia Medics, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.